|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Cure_Pharmaceutical_Holding_Corp.
Virttu Biologics
|
|
gptkbp:businessModel
|
research and development
strategic partnerships
commercialization of products
|
|
gptkbp:CEO
|
gptkb:Henry_Ji
|
|
gptkbp:clinicalTrials
|
gptkb:Asia
gptkb:United_States
Europe
Phase 1
Phase 2
Phase 3
ongoing studies
cancer therapies
biopharmaceutical company
positive outcomes
COVID-19 treatments
pain relief products
promising efficacy
|
|
gptkbp:collaborations
|
government agencies
academic institutions
biopharmaceutical companies
|
|
gptkbp:employees
|
over 100
|
|
gptkbp:focus
|
oncology
immunotherapy
pain management
|
|
gptkbp:founded
|
2006
|
|
gptkbp:founder
|
gptkb:Henry_Ji
|
|
gptkbp:headquarters
|
gptkb:San_Diego,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sorrento Therapeutics
|
|
gptkbp:investmentFocus
|
institutional investors
retail investors
|
|
gptkbp:market
|
approximately $300 million (2021)
|
|
gptkbp:partnerships
|
gptkb:Mayo_Clinic
gptkb:University_of_California,_Los_Angeles
gptkb:Cleveland_Clinic_Innovations
gptkb:University_of_California,_San_Diego
gptkb:University_of_Southern_California
gptkb:Cleveland_Clinic
gptkb:Scripps_Research_Institute
|
|
gptkbp:patentType
|
gptkb:COVI-MSC
ZTlido
|
|
gptkbp:products
|
gptkb:COVI-MSC
COVI-TEST
COVI-TRACK
ZTlido
|
|
gptkbp:research_focus
|
monoclonal antibodies
small molecules
cell therapies
|
|
gptkbp:revenue
|
$20 million (2020)
|
|
gptkbp:sells
|
gptkb:SRNE
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:SRNE
|
|
gptkbp:website
|
www.sorrentotherapeutics.com
|